Neurodegenerative Disease Therapeutics Market to Reach US$28.78 Billion by 2033 as Alzheimer's, Parkinson's, ALS and Huntington's Disease Create a High-Unmet-Need Treatment Frontier

NEW YORK, May 24, 2026 - According to DataM Intelligence, the global Neurodegenerative Disease Therapeutics Market reached US$12.52 billion in 2024 and is expected to reach US$28.78 billion by 2033, growing at a CAGR of 9.8% during 2025 to 2033. The market is segmented by drug class into dopamine agonists, decarboxylase inhibitors, cholinesterase inhibitors, immunomodulators and others, and by disease type into Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease, Huntington disease and others.

The global neurodegenerative disease therapeutics market is entering a high-value growth phase as aging populations, rising neurological disease burden and new treatment approvals increase demand for therapies that address Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington disease and related disorders. On a growth-multiple basis, the market is expected to expand nearly 2.30x by 2033, reflecting the growing commercial importance of chronic, progressive and high-unmet-need neurological conditions.

Request Executive Sample | Market Intelligence: https://www.datamintelligence.com/download-sample/neurodegenerative-disease-therapeutics-market?kailas

Why Neurodegenerative Disease Therapeutics Is a Highly Sellable Market

Neurodegenerative disease therapeutics is highly sellable because it covers multiple high-burden disorders with long treatment timelines, limited curative options and substantial unmet clinical need. Unlike narrow treatment categories focused on a single indication, this market spans Alzheimer's disease, Parkinson's disease, ALS, Huntington disease and other progressive neurological disorders. Each condition creates demand for symptom management, disease-modifying research, caregiver support, long-term medication use and specialized clinical care.

The market's importance is reinforced by the scale of neurological disease burden. WHO reported that 57 million people had dementia worldwide in 2021, with nearly 10 million new cases each year, and Alzheimer's disease may contribute to 60% to 70% of dementia cases. Parkinson's disease also represents a major and rising burden, with WHO reporting that global prevalence doubled over 25 years and reached more than 8.5 million people in 2019.

Aging Populations Create a Durable Demand Base

The strongest structural driver for the market is aging. Neurodegenerative disorders are strongly associated with older age, and the growing elderly population is increasing the number of patients requiring long-term neurological care. DataM Intelligence notes that rising prevalence of disorders such as Alzheimer's, Parkinson's and Huntington's disease, particularly among aging populations, is fueling demand for effective treatment options. The report also highlights that an estimated 6.9 million Americans aged 65 and older were living with Alzheimer's in 2024.

This aging-linked demand gives the market long-term commercial durability. Patients often require ongoing therapy over many years, and disease progression can create evolving treatment needs across early, moderate and advanced stages. As diagnosis improves and access to neurological care expands, the addressable treatment population is expected to grow across both mature and emerging healthcare markets.

Innovative Approvals Are Shifting the Market Beyond Symptom Control

Rising approvals for innovative drugs are expected to significantly drive market growth. DataM Intelligence highlights that regulatory bodies such as the FDA and EMA have approved therapies for Alzheimer's disease, Parkinson's disease, multiple sclerosis and ALS, including treatments that aim not only to manage symptoms but also to modify disease progression in selected patient populations.

Recent approvals show how quickly the market is evolving. In May 2024, Biogen announced European Commission approval under exceptional circumstances for QALSODY, or tofersen, for adults with ALS linked to SOD1 mutations. In September 2024, Roche received FDA approval for OCREVUS ZUNOVO, a twice-yearly subcutaneous injection for relapsing and primary progressive multiple sclerosis. In January 2024, AbbVie launched PRODUODOPA in the European Union for advanced Parkinson's disease with severe motor fluctuations.

Parkinson's Disease Supports Strong Demand for Dopamine Agonists

Dopamine agonists are expected to hold 24.8% of the market share in 2024, making them a leading drug-class segment in neurodegenerative disease therapeutics. Their strength is tied to their central role in managing Parkinson's disease and other dopamine-related neurological conditions. These drugs are commonly used in early Parkinson's disease to delay levodopa initiation and help reduce long-term motor complications.

The segment is also supported by continued innovation. In September 2024, AbbVie announced positive topline results from its pivotal Phase 3 TEMPO-1 trial evaluating tavapadon, a once-daily investigational D1/D5 dopamine receptor partial agonist, as monotherapy for early Parkinson's disease. This reinforces the commercial relevance of improved dopamine-targeting therapies that can address symptoms such as tremors, rigidity and bradykinesia while improving long-term treatment convenience.

ALS and Huntington's Disease Add High-Unmet-Need Commercial Depth

ALS and Huntington's disease strengthen the market's sellability because they are severe, progressive and difficult-to-treat conditions with limited therapeutic options. The U.S. CDC's National ALS Registry dashboard projects 34,720 adults living with ALS in the United States in 2026, highlighting the continued need for therapies that slow progression, improve function and support quality of life.

Huntington's disease is also gaining stronger pharmaceutical attention. DataM Intelligence notes that in December 2024, Novartis entered a global licensing and partnership agreement with PTC Therapeutics to advance PTC518, an investigational oral therapy for Huntington's disease. This agreement reflects growing interest in therapies targeting genetically defined and high-unmet-need neurodegenerative conditions.

North America Leads with 37.6% Market Share

North America is expected to hold 37.6% of the global neurodegenerative disease therapeutics market in 2024, supported by rising disease prevalence, strong R&D activity, multinational pharmaceutical presence, regulatory support and increasing funding for neurodegenerative disease research. DataM Intelligence reports that in March 2024, an additional US$100 million was allocated to the U.S. National Institutes of Health, bringing annual federal funding for Alzheimer's research to approximately US$3.8 billion.

Regional growth is also supported by drug approvals. In August 2024, Amneal Pharmaceuticals received FDA approval for CREXONT, an extended-release carbidopa and levodopa capsule for Parkinson's disease. In May 2024, Teva Pharmaceuticals received FDA approval for AUSTEDO XR, a once-daily treatment for tardive dyskinesia and Huntington's disease chorea in adults.

Asia Pacific Becomes a Fast-Growing Opportunity Zone

Asia Pacific is expected to hold 22.8% of the global market in 2024 and is experiencing rapid growth due to increasing prevalence of neurodegenerative disorders, expanding healthcare demand and rising R&D activity in countries such as China, India and Japan. DataM Intelligence notes that the region's pharmaceutical industry, including multinational and local companies, is strengthening therapy availability through innovation and regulatory approvals.

A notable example is Otsuka Pharmaceutical's September 2024 regulatory approval in Japan for an expanded indication of Rexulti, targeting symptoms such as excessive motor activity and aggressive behavior linked to mood fluctuations and irritability in patients with Alzheimer's disease dementia. This development highlights how regional markets are expanding beyond traditional symptom management into more specific neuropsychiatric and behavioral treatment needs.

Safety and Side Effects Remain Key Market Restraints

Despite strong market momentum, safety concerns remain a major barrier. DataM Intelligence notes that many neurodegenerative disease therapies, especially novel or disease-modifying treatments, can cause adverse reactions ranging from mild symptoms to serious complications. These safety issues can affect patient adherence, physician prescribing confidence, regulatory approval timelines and overall market penetration.

The challenge is particularly important because neurodegenerative disorders often affect older patients with comorbidities. This makes tolerability, dosing convenience, long-term safety and monitoring requirements essential factors in commercialization. Therapies that can balance efficacy, safety and patient convenience are likely to gain stronger adoption as the market matures.

Competitive Landscape: Global Neurology Leaders Compete Across Innovation, Access and Disease Modification

The global neurodegenerative disease therapeutics market includes major companies such as AbbVie Inc., Amneal Pharmaceuticals LLC, Eisai Co., Ltd., F. Hoffmann-La Roche Ltd, Merck KGaA, Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co., Ltd. and Orion Corporation. These companies compete across Parkinson's disease, Alzheimer's disease, ALS, Huntington disease and related neurological disorders.

Recent developments show strong market activity. In February 2025, Supernus Pharmaceuticals received FDA approval for ONAPGO, the first and only subcutaneous apomorphine infusion device for managing motor fluctuations in adults with advanced Parkinson's disease. In January 2025, Eisai and Biogen received FDA approval for a supplemental Biologics License Application for LEQEMBI, allowing once-every-four-weeks intravenous maintenance dosing for Alzheimer's disease patients at the mild cognitive impairment or mild dementia stage.

Purchase Corporate License | Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=neurodegenerative-disease-therapeutics-market?kailas

Strategic Outlook: Neurodegenerative Disease Therapeutics Becomes a Core High-Unmet-Need Neurology Market

The neurodegenerative disease therapeutics market is positioned for sustained growth because it addresses a broad set of progressive, disabling and high-burden disorders with limited curative options. The projected rise from US$12.52 billion in 2024 to US$28.78 billion by 2033 reflects increasing demand for both established symptomatic therapies and emerging disease-modifying approaches.

The next phase of growth will be shaped by aging populations, earlier diagnosis, disease-modifying therapies, dopamine agonist innovation, ALS and Huntington's disease pipelines, Alzheimer's biologics, advanced delivery systems and regional treatment access. Because this market covers Alzheimer's, Parkinson's, ALS, Huntington's disease and other high-burden neurological conditions, it offers a rare combination of broad disease coverage, recurring treatment demand, strong unmet need and long-term pharmaceutical innovation.

About the Report

The Neurodegenerative Disease Therapeutics Market report by DataM Intelligence analyzes the market by drug class, disease type, route of administration and region. Drug class coverage includes dopamine agonists, decarboxylase inhibitors, cholinesterase inhibitors, immunomodulators and others. Disease type coverage includes Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease, Huntington disease and others, with regional coverage across North America, Latin America, Europe, Asia Pacific, the Middle East and Africa.

Contact:
Fabian
DataM Intelligence 4market Research LLP
6th Floor, M2 Tech Hub, DataM Intelligence 4market Research LLP, Lalitha Nagar, Habsiguda, Secunderabad, Hyderabad, Telangana 500039
USA: +1 877-441-4866
UK: +44 161-870-5507
Email: fabian@datamintelligence.com

About DataM Intelligence
DataM Intelligence is a renowned provider of market research, delivering deep insights through pricing analysis, market share breakdowns, and competitive intelligence. The company specializes in strategic reports that guide businesses in high-growth sectors such as nutraceuticals and AI-driven health innovations.
To find out more, visit https://www.datamintelligence.com/ or follow us on Twitter, LinkedIn and Facebook.

This release was published on openPR.